A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type <i>KRAS</i> who have received first‐line systemic therapy

Cathy Eng, Alberto Bessudo, Lowell L. Hart, A. Severtsev, Oleg Gladkov, Lothar Müller, М. В. Копп, Vladimir Vladimirov, Robert M. Langdon, Б. Н. Котив, Sandro Barni, Ching Hsu, Ellen Bolotin, Reinhard von Roemeling, Brian Schwartz, Johanna C. Bendell

International Journal of Cancer, 2016

The University of Texas MD Anderson Cancer Center, California Cancer Associates for Research and Excellence, Florida Cancer Specialists & Research Institute, Sarah Cannon, Central Clinical Hospital and Polyclinic, Chelyabinsk Regional Clinical Oncology Center, University of Applied Sciences Emden Leer, Samara Regional Clinical Oncology Center, Pyatigorsk Oncology Center, Methodist Hospital, Houston Methodist, Nebraska Methodist College, S. M. Kirov Military Medical Academy, Azienda Ospedaliera Treviglio, Daiichi Sankyo (United States), Daiichi Sankyo (Germany), Bayer (United States), Arqule (United States), Tennessee Oncology

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with International Journal of Cancer. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

Citations

View on Google Scholar

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type <i>KRAS</i> who have received first‐line systemic therapy

Abstract

Journal Details

Join JournalsHub

Welcome Back